Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 520

1.

Histopathology of thymectomy specimens from the MGTX-trial: Entropy analysis as strategy to quantify spatial heterogeneity of lymphoid follicle and fat distribution.

Weis CA, Aban IB, Cutter G, Kaminski HJ, Scharff C, Grießmann BW, Deligianni M, Kayser K, Wolfe GI, Ströbel P, Marx A.

PLoS One. 2018 Jun 13;13(6):e0197435. doi: 10.1371/journal.pone.0197435. eCollection 2018.

2.

Divergent effects of AKI to CKD models on inflammation and fibrosis.

Black L, Lever JM, Traylor AM, Chen B, Yang Z, Esman S, Jiang Y, Cutter G, Boddu R, George J, Agarwal A.

Am J Physiol Renal Physiol. 2018 Jun 13. doi: 10.1152/ajprenal.00179.2018. [Epub ahead of print]

PMID:
29897282
3.

Mortality in neuromyelitis optica is strongly associated with African ancestry.

Mealy MA, Kessler RA, Rimler Z, Reid A, Totonis L, Cutter G, Kister I, Levy M.

Neurol Neuroimmunol Neuroinflamm. 2018 Jun 7;5(4):e468. doi: 10.1212/NXI.0000000000000468. eCollection 2018 Jul. No abstract available.

4.

Predictive validity of NEDA in the 16- and 21-year follow-up from the pivotal trial of interferon beta-1b.

Goodin DS, Reder AT, Traboulsee AL, Li DK, Langdon D, Cutter G, Cook S, O'Donnell T, Kremenchutzky M, Oger J, Koelbach R, Pohl C, Wicklein EM; IFNB Multiple Sclerosis Study Group and the 16- and 21-Year LTF Investigators.

Mult Scler. 2018 May 1:1352458518773511. doi: 10.1177/1352458518773511. [Epub ahead of print]

PMID:
29761737
5.

Understanding and Preventing Loss to Follow-up: Experiences From the Spinal Cord Injury Model Systems.

Kim H, Cutter GR, George B, Chen Y.

Top Spinal Cord Inj Rehabil. 2018 Spring;24(2):97-109. doi: 10.1310/sci2402-97.

PMID:
29706754
6.

DuraGraft vascular conduit preservation solution in patients undergoing coronary artery bypass grafting: rationale and design of a within-patient randomised multicentre trial.

Ben Ali W, Voisine P, Olsen PS, Jeanmart H, Noiseux N, Goeken T, Satishchandran V, Cademartiri F, Cutter G, Veerasingam D, Brown C, Emmert MY, Perrault LP.

Open Heart. 2018 Apr 13;5(1):e000780. doi: 10.1136/openhrt-2018-000780. eCollection 2018.

7.

Phase II Randomized Controlled Trial of Constraint-Induced Movement Therapy in Multiple Sclerosis. Part 1: Effects on Real-World Function.

Mark VW, Taub E, Uswatte G, Morris DM, Cutter GR, Adams TL, Bowman MH, McKay S.

Neurorehabil Neural Repair. 2018 Mar;32(3):223-232. doi: 10.1177/1545968318761050.

PMID:
29668399
8.

Declining Financial Capacity in Mild Cognitive Impairment: A Six-Year Longitudinal Study.

Martin RC, Gerstenecker A, Triebel KL, Falola M, McPherson T, Cutter G, Marson DC.

Arch Clin Neuropsychol. 2018 Mar 31. doi: 10.1093/arclin/acy030. [Epub ahead of print]

PMID:
29617705
9.

A survey of dietary characteristics in a large population of people with multiple sclerosis.

Fitzgerald KC, Tyry T, Salter A, Cofield SS, Cutter G, Fox RJ, Marrie RA.

Mult Scler Relat Disord. 2018 May;22:12-18. doi: 10.1016/j.msard.2018.02.019. Epub 2018 Feb 27.

PMID:
29510324
10.

Factors associated with excessive sitting time in multiple sclerosis.

Sasaki JE, Motl RW, Cutter G, Marrie RA, Tyry T, Salter A.

Mult Scler Relat Disord. 2018 Apr;21:71-77. doi: 10.1016/j.msard.2018.02.009. Epub 2018 Feb 10.

PMID:
29477021
11.

Gender and quality of life in myasthenia gravis patients from the myasthenia gravis foundation of America registry.

Lee I, Kaminski HJ, Xin H, Cutter G.

Muscle Nerve. 2018 Feb 21. doi: 10.1002/mus.26104. [Epub ahead of print]

PMID:
29466829
12.

Occupational Therapy Treatment to Improve Upper Extremity Function in Individuals with Early Systemic Sclerosis: A Pilot Study.

Murphy SL, Barber M, Homer K, Dodge C, Cutter G, Khanna D.

Arthritis Care Res (Hoboken). 2018 Jan 30. doi: 10.1002/acr.23522. [Epub ahead of print]

PMID:
29381834
13.

National estimates of self-reported sitting time in adults with multiple sclerosis.

Sasaki JE, Motl RW, Cutter G, Marrie RA, Tyry T, Salter A.

Mult Scler J Exp Transl Clin. 2018 Jan 19;4(1):2055217318754368. doi: 10.1177/2055217318754368. eCollection 2018 Jan-Mar.

14.

Defining standard enzymatic dissociation methods for individual brains and spinal cords in EAE.

Hussain RZ, Miller-Little WA, Doelger R, Cutter GR, Loof N, Cravens PD, Stüve O.

Neurol Neuroimmunol Neuroinflamm. 2018 Jan 17;5(2):e437. doi: 10.1212/NXI.0000000000000437. eCollection 2018 Mar.

15.

Treatment satisfaction and bothersome bladder, bowel, sexual symptoms in multiple sclerosis.

Wang G, Marrie RA, Fox RJ, Tyry T, Cofield SS, Cutter GR, Salter A.

Mult Scler Relat Disord. 2018 Feb;20:16-21. doi: 10.1016/j.msard.2017.12.006. Epub 2017 Dec 14.

PMID:
29275057
16.

Neurofibromatosis Clinical Trial Consortium.

Packer RJ, Fisher MJ, Cutter G, Cole-Plourde K, Korf BR.

J Child Neurol. 2018 Jan;33(1):82-91. doi: 10.1177/0883073817739196.

PMID:
29246097
17.

Accuracy of Blood Pressure Measurement Devices in Pregnancy: A Systematic Review of Validation Studies.

Bello NA, Woolley JJ, Cleary KL, Falzon L, Alpert BS, Oparil S, Cutter G, Wapner R, Muntner P, Tita AT, Shimbo D.

Hypertension. 2018 Feb;71(2):326-335. doi: 10.1161/HYPERTENSIONAHA.117.10295. Epub 2017 Dec 11.

PMID:
29229741
18.

Diet quality is associated with disability and symptom severity in multiple sclerosis.

Fitzgerald KC, Tyry T, Salter A, Cofield SS, Cutter G, Fox R, Marrie RA.

Neurology. 2018 Jan 2;90(1):e1-e11. doi: 10.1212/WNL.0000000000004768. Epub 2017 Dec 6.

PMID:
29212827
19.

Perspectives on marijuana use and effectiveness: A survey of NARCOMS participants.

Cofield SS, Salter A, Tyry T, Crowe C, Cutter GR, Fox RJ, Marrie RA.

Neurol Clin Pract. 2017 Aug;7(4):333-343. doi: 10.1212/CPJ.0000000000000383.

PMID:
29185555
20.

A Randomized Trial of an Advanced Sun Safety Intervention for Vacationers at 41 North American Resorts.

Andersen PA, Buller DB, Walkosz BJ, Scott MD, Beck L, Liu X, Abbott A, Eye R, Cutter G.

J Health Commun. 2017 Dec;22(12):951-963. doi: 10.1080/10810730.2017.1382615. Epub 2017 Nov 21.

PMID:
29161214
21.

Prevalence of Sun Protection at Outdoor Recreation and Leisure Venues at Resorts in North America.

Walkosz BJ, Scott MD, Buller DB, Andersen PA, Beck L, Cutter GR.

Am J Health Educ. 2017;48(2):90-99. doi: 10.1080/19325037.2016.1271755. Epub 2017 Mar 10.

22.

Long-term follow-up of a randomized study of combination interferon and glatiramer acetate in multiple sclerosis: Efficacy and safety results up to 7 years.

Lublin FD, Cofield SS, Cutter GR, Gustafson T, Krieger S, Narayana PA, Nelson F, Salter AR, Wolinsky JS.

Mult Scler Relat Disord. 2017 Nov;18:95-102. doi: 10.1016/j.msard.2017.09.012. Epub 2017 Sep 23.

PMID:
29141831
23.

Trigeminal Neuralgia Commonly Precedes the Diagnosis of Multiple Sclerosis.

Fallata A, Salter A, Tyry T, Cutter GR, Marrie RA.

Int J MS Care. 2017 Sep-Oct;19(5):240-246. doi: 10.7224/1537-2073.2016-065.

24.

Learning from the past: reflections on recently completed myasthenia gravis trials.

Benatar M, Howard JF Jr, Barohn R, Wolfe GI, Cutter G.

Ann N Y Acad Sci. 2018 Jan;1412(1):5-13. doi: 10.1111/nyas.13501. Epub 2017 Oct 24.

PMID:
29064567
25.

Clinical trial design for progressive MS trials.

Pardini M, Cutter G, Sormani MP.

Mult Scler. 2017 Oct;23(12):1642-1648. doi: 10.1177/1352458517729461. Review.

PMID:
29041873
26.

Coastal ocean and shelf-sea biogeochemical cycling of trace elements and isotopes: lessons learned from GEOTRACES.

Charette MA, Lam PJ, Lohan MC, Kwon EY, Hatje V, Jeandel C, Shiller AM, Cutter GA, Thomas A, Boyd PW, Homoky WB, Milne A, Thomas H, Andersson PS, Porcelli D, Tanaka T, Geibert W, Dehairs F, Garcia-Orellana J.

Philos Trans A Math Phys Eng Sci. 2016 Nov 28;374(2081). pii: 20160076. doi: 10.1098/rsta.2016.0076. Review.

27.

Pedestrian safety in patients with Parkinson's disease: A case-control study.

Ford KJ, Joop A, Memon RA, Wood KH, Ball K, Cutter GR, Schwebel DC, Amara AW.

Mov Disord. 2017 Dec;32(12):1748-1755. doi: 10.1002/mds.27124. Epub 2017 Oct 4.

PMID:
28976016
28.

Author response: High hypothetical interest in physician-assisted death in multiple sclerosis.

Marrie RA, Salter A, Tyry T, Cutter GR, Fox RJ.

Neurology. 2017 Sep 26;89(13):1429-1430. doi: 10.1212/WNL.0000000000004437. No abstract available.

PMID:
28947584
29.

Effects of subthalamic nucleus deep brain stimulation on objective sleep outcomes in Parkinson's disease.

Amara AW, Walker HC, Joop A, Cutter G, DeWolfe JL, Harding SM, Standaert DG.

Mov Disord Clin Pract. 2017 Mar-Apr;4(2):183-190. doi: 10.1002/mdc3.12375. Epub 2016 Jun 6.

30.

Which symptoms contribute the most to patients' perception of health in multiple sclerosis?

Green R, Cutter G, Friendly M, Kister I.

Mult Scler J Exp Transl Clin. 2017 Sep 5;3(3):2055217317728301. doi: 10.1177/2055217317728301. eCollection 2017 Jul-Sep.

31.

Prevalence odds ratio versus prevalence ratio: choice comes with consequences.

Tamhane AR, Westfall AO, Burkholder GA, Cutter GR.

Stat Med. 2017 Oct 15;36(23):3760. doi: 10.1002/sim.7375. Epub 2017 Jul 6. No abstract available.

PMID:
28872254
32.

The MSOAC approach to developing performance outcomes to measure and monitor multiple sclerosis disability.

LaRocca NG, Hudson LD, Rudick R, Amtmann D, Balcer L, Benedict R, Bermel R, Chang I, Chiaravalloti ND, Chin P, Cohen JA, Cutter GR, Davis MD, DeLuca J, Feys P, Francis G, Goldman MD, Hartley E, Kapoor R, Lublin F, Lundstrom G, Matthews PM, Mayo N, Meibach R, Miller DM, Motl RW, Mowry EM, Naismith R, Neville J, Panagoulias J, Panzara M, Phillips G, Robbins A, Sidovar MF, Smith KE, Sperling B, Uitdehaag BM, Weaver J; Multiple Sclerosis Outcome Assessments Consortium (MSOAC).

Mult Scler. 2017 Aug 1:1352458517723718. doi: 10.1177/1352458517723718. [Epub ahead of print]

33.

Interactions between cannabidiol and commonly used antiepileptic drugs.

Gaston TE, Bebin EM, Cutter GR, Liu Y, Szaflarski JP; UAB CBD Program.

Epilepsia. 2017 Sep;58(9):1586-1592. doi: 10.1111/epi.13852. Epub 2017 Aug 6.

PMID:
28782097
34.

Dysregulation of 14-3-3 proteins in neurodegenerative diseases with Lewy body or Alzheimer pathology.

McFerrin MB, Chi X, Cutter G, Yacoubian TA.

Ann Clin Transl Neurol. 2017 Jun 7;4(7):466-477. doi: 10.1002/acn3.421. eCollection 2017 Jul.

35.

Comparative utility of disability progression measures in PPMS: Analysis of the PROMiSe data set.

Koch MW, Cutter GR, Giovannoni G, Uitdehaag BMJ, Wolinsky JS, Davis MD, Steinerman JR, Knappertz V.

Neurol Neuroimmunol Neuroinflamm. 2017 May 10;4(4):e358. doi: 10.1212/NXI.0000000000000358. eCollection 2017 Jul.

36.

Laquinimod has no effects on brain volume or cellular CNS composition in the F1 3xTg-AD/C3H mouse model of Alzheimer's disease.

Hussain RZ, Miller-Little WA, Lambracht-Washington D, Jaramillo TC, Takahashi M, Zhang S, Fu M, Cutter GR, Hayardeny L, Powell CM, Rosenberg RN, Stüve O.

J Neuroimmunol. 2017 Aug 15;309:100-110. doi: 10.1016/j.jneuroim.2017.05.017. Epub 2017 May 26.

PMID:
28601278
37.

Erratum to: Assessing the feasibility of the Effectiveness of Discontinuing Bisphosphonates trial: a pilot study.

Wright NC, Foster PJ, Mudano AS, Melnick JA, Lewiecki EM, Shergy WJ, Curtis JR, Cutter GR, Danila MI, Kilgore ML, Lewis EC, Morgan SL, Redden DT, Warriner AH, Saag KG.

Osteoporos Int. 2017 Aug;28(8):2505. doi: 10.1007/s00198-017-4105-1. No abstract available.

PMID:
28593448
38.

Challenging Assumptions About African American Participation in Alzheimer Disease Trials.

Kennedy RE, Cutter GR, Wang G, Schneider LS.

Am J Geriatr Psychiatry. 2017 Oct;25(10):1150-1159. doi: 10.1016/j.jagp.2017.04.013. Epub 2017 Apr 25.

PMID:
28554539
39.

Assessing the feasibility of the Effectiveness of Discontinuing Bisphosphonates trial: a pilot study.

Wright NC, Foster PJ, Mudano AS, Melnick JA, Lewiecki ME, Shergy WJ, Curtis JR, Cutter GR, Danila MI, Kilgore ML, Lewis EC, Morgan SL, Redden DT, Warriner AH, Saag KG.

Osteoporos Int. 2017 Aug;28(8):2495-2503. doi: 10.1007/s00198-017-4073-5. Epub 2017 May 24. Erratum in: Osteoporos Int. 2017 Jun 7;:.

40.

A contemporary profile of primary progressive multiple sclerosis participants from the NARCOMS Registry.

Salter A, Thomas NP, Tyry T, Cutter GR, Marrie RA.

Mult Scler. 2018 Jun;24(7):951-962. doi: 10.1177/1352458517711274. Epub 2017 May 19.

PMID:
28524746
41.

The Virtual Short Physical Performance Battery: Psychometric Properties and Validation in Older Adults With Multiple Sclerosis.

Bollaert RE, Marsh AP, Cutter GR, Motl RW.

J Appl Gerontol. 2017 May 1:733464817709532. doi: 10.1177/0733464817709532. [Epub ahead of print]

PMID:
28506093
42.

Neurocognitive Predictors of Declining Financial Capacity in Persons with Mild Cognitive Impairment.

Niccolai LM, Triebel KL, Gerstenecker A, McPherson TO, Cutter GR, Martin RC, Marson DC.

Clin Gerontol. 2017 Jan-Feb;40(1):14-23. doi: 10.1080/07317115.2016.1228022. Epub 2016 Sep 1.

43.

Results of a Randomized Trial on an Intervention Promoting Adoption of Occupational Sun Protection Policies.

Buller DB, Walkosz BJ, Buller MK, Wallis A, Andersen PA, Scott MD, Eye R, Liu X, Cutter G.

Am J Health Promot. 2018 May;32(4):1042-1053. doi: 10.1177/0890117117704531. Epub 2017 Apr 27.

PMID:
28447466
44.

Upper limb impairment is associated with use of assistive devices and unemployment in multiple sclerosis.

Marrie RA, Cutter GR, Tyry T, Cofield SS, Fox R, Salter A.

Mult Scler Relat Disord. 2017 Apr;13:87-92. doi: 10.1016/j.msard.2017.02.013. Epub 2017 Feb 20.

PMID:
28427709
45.

Association Between Early Childhood Caries and Colonization with Streptococcus mutans Genotypes From Mothers.

Childers NK, Momeni SS, Whiddon J, Cheon K, Cutter GR, Wiener HW, Ghazal TS, Ruby JD, Moser SA.

Pediatr Dent. 2017 Mar 15;39(2):130-135.

46.

Evaluating risk factors for chronic kidney disease in pediatric patients with sickle cell anemia.

Lebensburger JD, Cutter GR, Howard TH, Muntner P, Feig DI.

Pediatr Nephrol. 2017 Sep;32(9):1565-1573. doi: 10.1007/s00467-017-3658-8. Epub 2017 Apr 5.

PMID:
28382567
47.

Comparative effectiveness of delayed-release dimethyl fumarate versus glatiramer acetate in multiple sclerosis patients: results of a matching-adjusted indirect comparison.

Chan A, Cutter G, Fox RJ, Xiao J, Lewin JB, Edwards MR.

J Comp Eff Res. 2017 Jun;6(4):313-323. doi: 10.2217/cer-2016-0085. Epub 2017 Mar 28.

48.

High hypothetical interest in physician-assisted death in multiple sclerosis.

Marrie RA, Salter A, Tyry T, Cutter GR, Cofield S, Fox RJ.

Neurology. 2017 Apr 18;88(16):1528-1534. doi: 10.1212/WNL.0000000000003831. Epub 2017 Mar 15.

PMID:
28298551
49.

Is multiple sclerosis a length-dependent central axonopathy? The case for therapeutic lag and the asynchronous progressive MS hypotheses.

Giovannoni G, Cutter G, Sormani MP, Belachew S, Hyde R, Koendgen H, Knappertz V, Tomic D, Leppert D, Herndon R, Wheeler-Kingshott CAM, Ciccarelli O, Selwood D, di Cantogno EV, Ben-Amor AF, Matthews P, Carassiti D, Baker D, Schmierer K.

Mult Scler Relat Disord. 2017 Feb;12:70-78. doi: 10.1016/j.msard.2017.01.007. Epub 2017 Jan 17. Review.

PMID:
28283111
50.

A Framework of Care in Multiple Sclerosis, Part 2: Symptomatic Care and Beyond.

Newsome SD, Aliotta PJ, Bainbridge J, Bennett SE, Cutter G, Fenton K, Lublin F, Northrop D, Rintell D, Walker BD, Weigel M, Zackowski K, Jones DE.

Int J MS Care. 2017 Jan-Feb;19(1):42-56. doi: 10.7224/1537-2073.2016-062.

Supplemental Content

Loading ...
Support Center